Technical Analysis for VRTX - Vertex Pharmaceuticals Incorporated
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Down | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Inside Day | Range Contraction | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Gapped Down | Weakness | 0.00% | |
20 DMA Resistance | Bearish | -0.06% | |
Fell Below 20 DMA | Bearish | -0.82% | |
Outside Day | Range Expansion | -0.82% | |
Crossed Above 20 DMA | Bullish | -1.83% | |
MACD Bullish Signal Line Cross | Bullish | -1.83% | |
NR7 | Range Contraction | -1.83% | |
Narrow Range Bar | Range Contraction | -1.83% |
Alert | Time |
---|---|
Possible Inside Day | about 14 hours ago |
60 Minute Opening Range Breakout | about 17 hours ago |
10 DMA Resistance | about 18 hours ago |
Gap Down Closed | about 18 hours ago |
Reversed from Down | about 18 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/06/2024
Vertex Pharmaceuticals Incorporated Description
Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Its products include telaprevir for the treatment of adults with genotype 1 hepatitis C virus (HCV) infection, which is marketed in the United States and Canada under the INCIVEK brand name; and ivacaftor for the treatment of cystic fibrosis that is marketed in the United States, Canada, and Europe under the KALYDECO brand name. The company, through its collaboration agreement with Janssen Pharmaceutica, N.V., also markets telaprevir in Europe and other countries in Janssen's territories under the INCIVO brand name, as well as in Japan under TELAVIC brand name. It is also developing drug candidates for the treatment of cystic fibrosis, including VX-809, which is in Phase III clinical trial and VX-661 that is in Phase II clinical trial; and drug candidates for the treatment of HCV infection, such as VX-135 (ALS-2200), which is in Phase II clinical trial and VX-222 that is in Phase II clinical trial. In addition, the company develops VX-509, which is in Phase II clinical trial for the treatment of autoimmune disease; and VX-787 that is in Phase II clinical trial for the treatment of influenza. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: S&P 500 Nasdaq 100 Autoimmune Disease Organic Compounds Chemical Compounds Infection Influenza Breakthrough Therapy Cystic Fibrosis Hepatitis C Hepatitis C Virus Treatment Of Autoimmune Disease HCV Cyclopropanes Organofluorides Treatment Of Cystic Fibrosis Anilides Genotype HCV Infection
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 448.4 |
52 Week Low | 320.01 |
Average Volume | 985,351 |
200-Day Moving Average | 383.53 |
50-Day Moving Average | 411.76 |
20-Day Moving Average | 401.28 |
10-Day Moving Average | 397.32 |
Average True Range | 7.50 |
RSI (14) | 41.86 |
ADX | 26.77 |
+DI | 13.98 |
-DI | 24.76 |
Chandelier Exit (Long, 3 ATRs) | 398.95 |
Chandelier Exit (Short, 3 ATRs) | 413.52 |
Upper Bollinger Bands | 414.47 |
Lower Bollinger Band | 388.09 |
Percent B (%b) | 0.36 |
BandWidth | 6.57 |
MACD Line | -4.01 |
MACD Signal Line | -4.59 |
MACD Histogram | 0.5826 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 406.69 | ||||
Resistance 3 (R3) | 406.38 | 403.01 | 405.16 | ||
Resistance 2 (R2) | 403.01 | 400.66 | 403.16 | 404.64 | |
Resistance 1 (R1) | 400.24 | 399.21 | 401.63 | 400.55 | 404.13 |
Pivot Point | 396.87 | 396.87 | 397.56 | 397.02 | 396.87 |
Support 1 (S1) | 394.10 | 394.52 | 395.49 | 394.41 | 390.83 |
Support 2 (S2) | 390.73 | 393.07 | 390.88 | 390.32 | |
Support 3 (S3) | 387.96 | 390.73 | 389.81 | ||
Support 4 (S4) | 388.27 |